Related Experiment Video
Updated: Feb 18, 2026
A Modified Simple Method for Induction of Myocardial Infarction in Mice
Published on: December 3, 2021
Cardioprotective Effects of Morroniside in Rats Following Acute Myocardial Infarction
1Department of Experimental Animal Centre, XuanWu Hospital of Capital Medical University, Beijing, People's Republic of China.
Abstract:
The aim of this study is to investigate the cardioprotective effects of morroniside in rats following acute myocardial infarction. An acute myocardial infarction (AMI) was induced by ligating the anterior descending coronary artery (LAD) [1]. Following AMI, morroniside was administered intragastrically for 24 h at doses of 45, 90, and 180 mg/kg, respectively. Biomarkers such as creatine kinase (CK-MB), lactate dehydrogenase (LDH), ɑ-hydroxybutyrate dehydrogenase (ɑ-HBDH), and aspartate aminotransferase (AST) activities in AMI rats in the serum were detected with commercial kits [2]. Following AMI, morroniside was administered intragastrically for 72 h at doses of 45, 90, and 180 mg/kg/d, respectively. The expression of nuclear factor kappa B (NF-κB) in cardiac myocardium was detected by western blotting analysis. Meanwhile, cardiac function was measured by echocardiography. We observed morroniside decreased the levels of CK-MB, LDH, ɑ-HBDH, and AST activities in AMI rats after 24 h. We also found that morroniside reduced the expression of NF-κB in cardiac myocardium at 72 h post AMI rats. Further, cardiac function was improved by administration of morroniside. Collectively, our findings demonstrated that morroniside had cardioprotective effects in rats following acute myocardial infarction. Attenuation of inflammation might contribute to the cardioprotective effects of morroniside.
Insights
Morroniside demonstrates cardioprotective effects by reducing cardiac injury biomarkers and inflammation in rats with acute myocardial infarction (AMI). This natural compound improved cardiac function, suggesting potential therapeutic benefits.
Area of Science:
- Cardiovascular research
- Pharmacology
- Biochemistry
Background:
- Acute myocardial infarction (AMI) is a leading cause of mortality worldwide.
- Identifying novel therapeutic agents for myocardial protection is crucial.
- Morroniside, a compound derived from traditional medicine, warrants investigation for its potential cardioprotective properties.
Purpose of the Study:
- To investigate the cardioprotective effects of morroniside in a rat model of acute myocardial infarction.
- To evaluate the impact of morroniside on cardiac injury biomarkers and inflammatory pathways.
- To assess the functional recovery of the heart following morroniside administration.
Main Methods:
- Acute myocardial infarction (AMI) was induced in rats by ligating the anterior descending coronary artery (LAD).
- Morroniside was administered intragastrically at various doses (45, 90, 180 mg/kg).
- Cardiac function was assessed using echocardiography, serum biomarkers (CK-MB, LDH, ɑ-HBDH, AST) were measured, and myocardial NF-κB expression was analyzed via Western blotting.
Main Results:
- Morroniside administration significantly decreased serum levels of cardiac injury biomarkers (CK-MB, LDH, ɑ-HBDH, AST) at 24 hours post-AMI.
- The expression of nuclear factor kappa B (NF-κB) in the cardiac myocardium was reduced by morroniside at 72 hours post-AMI.
- Echocardiographic measurements indicated an improvement in cardiac function following morroniside treatment.
Conclusions:
- Morroniside exhibits significant cardioprotective effects in a rat model of acute myocardial infarction.
- The observed benefits may be attributed to the attenuation of inflammation, indicated by reduced NF-κB expression.
- These findings suggest that morroniside holds potential as a therapeutic agent for managing myocardial infarction.
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
01:30Cardiomyopathy II: Dilated Cardiomyopathy